Trial Profile
Prospective study investigating the clinical and radiological outcomes of patients with refractory/relapsed multiple sclerosis (RRMS) who discontinued natalizumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Dec 2015
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 23 Dec 2015 New trial record